The estimated Net Worth of Gregory Scott Duncan is at least $397 Thousand dollars as of 17 August 2023. Mr. Duncan owns over 25,000 units of CorMedix Inc stock worth over $397,056 and over the last 4 years he sold CRMD stock worth over $0. In addition, he makes $0 as Director at CorMedix Inc.
Sign up
Mr. Duncan CRMD stock SEC Form 4 insiders trading
Gregory has made over 6 trades of the CorMedix Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of CRMD stock worth $31,250 on 17 August 2023.
The largest trade he's ever made was buying 25,000 units of CorMedix Inc stock on 17 August 2023 worth over $31,250. On average, Gregory trades about 3,397 units every 60 days since 2020. As of 17 August 2023 he still owns at least 57,461 units of CorMedix Inc stock.
You can see the complete history of Mr. Duncan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gregory Duncan biography
Greg Duncan serves as Director of the Company. Mr. Duncan currently serves as the Chairman and CEO of Virios Therapeutics, a clinical-stage biopharmaceutical company developing and commercializing innovative antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM). Prior to joining his current company earlier this year, Mr. Duncan served as President and CEO of Celtaxsys, a privately held biotechnology company focused on cystic fibrosis and other rare, inflammatory diseases. Mr. Duncan spent the majority of his career in senior leadership roles in commercial stage pharmaceutical companies. He served as a senior executive at UCB, including as President of its North America business. In addition to acting on the executive committee and guiding the strategic direction for the Company’s specialty biopharma business, Mr. Duncan was responsible for managing a multi-billion dollar global business and overseeing the launches of multiple new products. Prior to his roles with UCB, Mr. Duncan spent approximately 18 years at Pfizer where he gained significant experience across sales and marketing functions including serving as SVP of US Marketing and later as President of Pfizer’s Latin America business. Mr. Duncan received his undergraduate degree from the State University of New York, Albany, and earned an MBA degree from Emory University.
What's Gregory Duncan's mailing address?
Gregory's mailing address filed with the SEC is C/O CORMEDIX INC.,, 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS, NJ, 07922.
Insiders trading at CorMedix Inc
Over the last 14 years, insiders at CorMedix Inc have traded over $693,980 worth of CorMedix Inc stock and bought 2,651,866 units worth $3,532,566 . The most active insiders traders include Mehmood Khan, Gary A. Gelbfish, and Brian Lenz. On average, CorMedix Inc executives and independent directors trade stock every 30 days with the average trade being worth of $199,105. The most recent stock trade was executed by Joseph Todisco on 13 March 2024, trading 13,561 units of CRMD stock currently worth $50,718.
What does CorMedix Inc do?
cormedix inc. is a company based out of 745 route 202-206, suite 303, bridgewater, nj, united states.
What does CorMedix Inc's logo look like?
Complete history of Mr. Duncan stock trades at CorMedix Inc and Virios Therapeutics
CorMedix Inc executives and stock owners
CorMedix Inc executives and other stock owners filed with the SEC include:
-
Khoso Baluch,
Chief Executive Officer, Interim Principal Accounting Officer, Director -
Phoebe Mounts,
Executive Vice President, General Counsel, Head of Regulatory, Compliance and Legal -
Elizabeth Masson,
Executive Vice President - Head of Clinical Operations -
Khoso Baluch,
CEO & Director -
Dr. Phoebe Mounts Esq.,
Exec. VP, Gen. Counsel, Sec. and Head of Regulatory, Compliance & Legal -
John Armstrong,
Executive Vice President - Technical Operations -
Elizabeth Masson-Hurlburt,
Exec. VP & Head of Clinical Operations -
John L. Armstrong Jr.,
Exec. VP for Technical Operations -
Alan Dunton,
Independent Director -
Myron Kaplan,
Independent Chairman of the Board -
Steven Lefkowitz,
Independent Director -
Janet Dillione,
Independent Director -
Gregory Duncan,
Director -
Paulo Costa,
Director -
Matthew David,
Chief Financial Officer, Executive Vice President -
Thomas Nusbickel,
Exec. VP & Chief Commercial Officer -
Dr. Paul Chew M.D.,
Acting Chief Medical Officer -
Dr. Paul Chew,
Acting Chief Medical Officer -
Dr. Matthew T. David M.D.,
Exec. VP & CFO -
Judith R Abrams,
Chief Medical Officer -
Robert W. Cook,
Chief Financial Officer -
Taunia Markvicka,
Director -
Antony Pfaffle,
Director -
Randy Milby,
Chief Operating Officer -
Cora M Tellez,
Director -
Mehmood Khan,
-
Michael W George,
Director -
Gary A. Gelbfish,
Director -
James Lefkowitz,
Director -
Bami Bastani,
Director -
Timothy M Hofer,
Secretary -
Mark T. Houser,
Chief Medical Officer -
John C. Houghton,
President and CEO -
Mark A. Klausner,
Chief Medical Officer -
Russell H Ellison,
Director -
Robert A Stewart,
-
Matthew Duffy,
Director -
Harry O'grady,
Chief Financial Officer -
Richard Cohen,
Director -
Development Inc Pharmabio,
10% owner -
Brian Lenz,
Chief Financial Officer -
Thomas Nusbickel,
EVP, Chief Commercial Officer -
Joseph Todisco,
Chief Executive Officer -
Kaufman Beth Zelnick,
Chief Legal Officer -
Erin Mistry,
Chief Commercial Officer